CalciMedica Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$21.2MTTM through 30 Jun 2026
Free Cash Flow -$19.1MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-385.3%ROE
-108.9%ROA
Balance Sheet Health
Debt / Equity1.22x
Current Ratio5.58x
Net Debt-$1.5Mnet cash position
Cash & Equivalents$18.6M
Quality Metrics
Altman Z-Score-15.57
Piotroski F-Score4 / 9
Earnings-Beat Rate25.0%
Multi-Year Trend
Diluted EPS-$1.37TTMFY2025: $-1.97
Dividend
No dividend
Capital Allocation
R&D Spend$12.5M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Auxora Program | $0 | View detailsFDA feedback on the design of a potential pivotal Auxora program in acute pancreatitis and potential future development in acute kidney injury is expected in Q2 2026. | |
| CM5480 Program | $0 | View detailsPreclinical and IND-enabling studies are advancing with an IND submission in pulmonary hypertension expected in 2027. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.